This company is no longer active
Enzon Pharmaceuticals (EZ1) Stock Overview
Focuses on non-edible cellulosic, fibrous, and plastic casings used to prepare and package processed meat and poultry products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
EZ1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Enzon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$0.29 |
| 52 Week Low | US$0.062 |
| Beta | 0.35 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -39.59% |
| 3 Year Change | -79.83% |
| 5 Year Change | -40.50% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.9% |
| 1Y | -39.6% | -8.0% | -0.8% |
Return vs Industry: EZ1 underperformed the German Biotechs industry which returned -20.5% over the past year.
Return vs Market: EZ1 underperformed the German Market which returned -1.9% over the past year.
Price Volatility
| EZ1 volatility | |
|---|---|
| EZ1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: EZ1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EZ1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Rick Feinstein | n/a |
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug.
Enzon Pharmaceuticals, Inc. Fundamentals Summary
| EZ1 fundamental statistics | |
|---|---|
| Market cap | €6.22m |
| Earnings (TTM) | -€224.54k |
| Revenue (TTM) | €24.22k |
Is EZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZ1 income statement (TTM) | |
|---|---|
| Revenue | US$26.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$26.00k |
| Other Expenses | US$267.00k |
| Earnings | -US$241.00k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0032 |
| Gross Margin | 100.00% |
| Net Profit Margin | -926.92% |
| Debt/Equity Ratio | 0% |
How did EZ1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/14 10:55 |
| End of Day Share Price | 2023/11/17 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Viskase Holdings, Inc. is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pamela Bassett | Cantor Fitzgerald & Co. |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |